Continuous Treatment With PREVENA Therapy for 14 Days

Inclusion Criteria:

• Subject is at least 22 years of age on the date of informed consent

• Subject can provide informed consent

• Subject requires a surgical procedure for 1 of the 4 specialty treatment groups (ie,lower extremity orthopedic procedure, abdominal or C-section procedure, sternotomy,or vascular procedure)

• Subject is willing and able to return for all scheduled study visits.

• Subject has 1 or more of the following risk factors for post-surgical complications:

• BMI ≥ 30

• diabetes

• history of smoking

• immune suppression or receiving drugs that can cause immune suppression (eg,steroids, chemotherapeutic medications, and/or antimetabolites)

• high risk for malnutrition, as indicated by 2 or more of the following1:

• insufficient energy intake

• loss of muscle mass

• loss of subcutaneous fat

• localized or generalized fluid accumulation that may mask weight loss

• diminished functional status as measured by hand-grip strength

• OR -

• has malnutrition, as determined by the investigator

• neutropenia

• cardiac, pulmonary, liver, or renal disease

• history of previous surgery or radiation in the treatment area

• Subject is pre-operatively assessed to undergo a procedure with a CDC WoundClassification of:

• Class I (Clean): An uninfected operative wound in which no inflammation isencountered, and the respiratory, alimentary, genital, or uninfected urinarytract is not entered

• OR -

• Class II (Clean Contaminated): An operative wound in which the respiratory,alimentary, genital, or uninfected urinary tract are entered under controlledconditions and without unusual contamination

• Subject has a closed post-surgical incision for which the anticipated duration ofPrevena Therapy is more than 11 days

Exclusion Criteria:

• Subject is female and, except in the case of C-section procedures, is pregnant orlactating prior to surgery

• Subject has signs of an infection in the surgical area or has signs of a systemicinfection at the time of surgery

• Subject is a chronic opioid user, defined per the CDC guidelines as opioid use for > 3 months, at the time of enrollment

• Subject has any of the following:

• condition(s) that, in the opinion of the investigator, cause the patient to bean overall health risk that is unsuitable for the surgery

• known sensitivity to the study product components (drape and/or dressingmaterials in direct contact with the closed incision or skin)

• known sensitivity to silver

• skin cancer localized at or in proximity to the incision site

• intraoperative issue(s) that precludes the use of Prevena Therapy

• Subject is preoperatively assessed to undergo a procedure with a CDC WoundClassification of:

• Class III (Contaminated): Open, fresh, accidental wounds, and/or major breaksin sterile technique or gross spillage from the gastrointestinal tract

• OR -

• Class IV (Dirty-Infected): Old traumatic wounds with retained devitalizedtissue and those that involve existing clinical infection or perforated viscera

• Subject is enrolled in another interventional clinical study